Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Thursday, October 24, 2019 at 2:30 PM IST to discuss the Company's Q2 FY20 Results. Please find attached herewith invitation for the same. Aarti Drugs Ltd - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2019.
We wish to inform you that Board of Directors at its Meeting held on Wednesday, October 23, 2019, approved the Audited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2019. Aarti Drugs Ltd - 524348 - Shareholding for the Period Ended September 30, 2019
Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Aarti Drugs Ltd - 524348 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Financial Results
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2019 ,inter alia, to consider and approve Audited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2019. Aarti Drugs Ltd - 524348 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Rushikesh DeoleDesignation :- Company Secretary and Compliance Officer Aarti Drugs Ltd - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates / Issue of Duplicate Share Certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. AARTI DRUGS LTD. - 524348 - Closure of Trading Window
This is to inform you that the Trading Window for trading in Equity Shares of the Company will remain closed from Tuesday, October 1, 2019 till the expiry of 48 hours after the declaration of financial results of the Company for the quarter and half year ended September 30, 2019. AARTI DRUGS LTD. - 524348 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aarti Industries Ltd